"10.1371_journal.pone.0129550","plos one","2015-06-17T00:00:00Z","Marie-Anne Vandenhende; Caroline Roussillon; Sandrine Henard; Philippe Morlat; Eric Oksenhendler; Hugues Aumaitre; Aurore Georget; Thierry May; Eric Rosenthal; Dominique Salmon; Patrice Cacoub; Dominique Costagliola; Geneviève Chêne; Fabrice Bonnet; the ANRS EN20 Mortalité 2010 study group","INSERM, ISPED, Centre INSERM U897-Epidémiologie-Biostatistiques, Bordeaux, France; Université Bordeaux, ISPED, Centre INSERM U897-Epidemiologie-Biostatistiques, Bordeaux, France; Service de médecine interne et maladies infectieuses, CHU de Bordeaux, Bordeaux, France; Service de Maladies Infectieuses, Hôpital Brabois, Vandoeuvre-Les-Nancy, France; Service d’Immunopathologie Clinique, Hôpital Saint Louis, AP-HP, Paris, France; Service des Maladies Infectieuses, Centre Hospitalier, Perpignan, France; Service de Médecine Interne, Hôpital de l’Archet, Nice, France; Université de Nice-Sophia Antipolis, Nice, France; Unité de Pathologie Infectieuse, Pôle Médecine, Hôpital Cochin, AP-HP, Paris, France; Université Paris Descartes, Paris, France; Service de Médecine Interne, Hôpital La Pitié-Salpêtrière, AP-HP, Paris, France; Université Pierre et Marie Curie, Paris, France; INSERM, UMR_S 1136, Institut Pierre Louis d’Epidémiologie et de Santé Publique, Paris, France; Sorbonne Universités, UPMC Université Paris 06, UMR_S 1136, Institut Pierre Louis d’Epidémiologie et de Santé Publique, Paris, France","Conceived and designed the experiments: M-AV CR PM TM ER DS PC GC FB. Performed the experiments: CR AG SH EO HA TM ER GC. Analyzed the data: M-AV CR PM AG DC GC FB. Wrote the paper: M-AV CR SH PM EO HA AG TM ER DS PC DC GC FB. Approved the final manuscript before submission: M-AV CR SH PM EO HA AG TM ER DS PC DC GC FB.","The authors have read the journal's policy and the authors of this manuscript have the following competing interests: CR, AG, EO and DS had no conflicts of interest to declare. M-AV has received honoraria or travel/meeting expenses from Gilead, Janssen-Cilag and Merck Sharp & Dohme-Chibret. SH has received travel/meeting expenses from Pfizer. PM has received honoraria or travel/meeting expenses from Bristol-Myers Squibb, Gilead, Janssen-Cilag, Merck Sharp & Dohme-Chibret and ViiV Healthcare. HA has received honoraria or travel/meeting expenses from Gilead, Janssen-Cilag and Merck Sharp & Dohme-Chibret. TM has received honoraria from Janssen Cilag and ViiV Healthcare. ER has received honoraria from Amgen, Bristol-Myers Squibb, Gilead, Janssen Cilag, Merck Sharp & Dohme-Chibret and Roche. PC has received honoraria from Astra Zeneca, Bayer, Boehringer Ingelheim, Gilead, Glaxo Smith Kline, Janssen-Cilag, Merck Sharp & Dohme-Chibret, Roche, Servier, and Vifor. DC has received honoraria from Abbott, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Janssen Cilag, Merck Sharp & Dohme-Chibret and Roche. GC has received consulting fees from Roche and has received travel grant from Lundbeck. GC has had scientific responsibilities in projects receiving specific grant supports that are managed through her Institution or a non-profit society: from the French Agency for Research on AIDS and Viral Hepatitis (ANRS), the European Commission (Framework Program 7), U.K. Medical Research Council, U.S. National Institute of Health (NIH), Fondation Plan Alzheimer, Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Chiron, Fit Biotech LTD, Gilead Sciences, GlaxoSmithKline, Jansen Cilag, Merck Sharp & Dohme-Chibret, Pfizer, Roche, Tibotec, ViiV Healthcare. GC serves as Academic Editor of PLOS ONE and is on the editorial board of BMC Infectious Diseases Journal. FB has received honoraria or travel/meeting expenses from Gilead, Janssen Cilag, Merck Sharp & Dohme-Chibret and ViiV Healthcare. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.","2015","06","Marie-Anne Vandenhende","MAV",15,TRUE,9,8,7,14,TRUE,TRUE,FALSE,0,NA,FALSE
